市场调查报告书
商品编码
1298803
2023-2028年按皮肤病、给药途径、分销渠道和地区分類的皮肤病药物市场Dermatological Drugs Market by Dermatological Diseases, Route of Administration, Distribution Channel, and Region 2023-2028 |
2022年,全球皮肤病药物市场规模达到215.8亿美元。展望未来,IMARC集团预计,到2028年,市场规模将达到391.1亿美元,在2023-2028年期间,增长率(CAGR)为10.25%。皮肤病发病率的上升,对药妆需求的增加,以及个人对皮肤健康认识的提高,是推动市场发展的一些关键因素。
皮肤病药物是用于治疗各种皮肤病的药物,包括痤疮、牛皮癣、湿疹、酒糟鼻、皮肤癌、真菌感染以及其他影响皮肤、头发和指甲的疾病。这些药物可以局部使用、口服或注射,这取决于所治疗的皮肤病类型。局部皮肤病药物,包括药膏、软膏、凝胶和喷雾剂,直接应用于皮肤。它们最常用于治疗局部皮肤病,如痤疮或湿疹。另一方面,全身性皮肤病药物是通过口服或注射,针对皮肤病的根本原因而发挥作用。这些药物通常用于治疗严重或广泛的皮肤病,如银屑病。这些产品具有美容和制药的特性,其目的是改善皮肤的整体健康和外观。此外,皮肤病药物是由皮肤科医生或其他具有皮肤健康专业知识的医疗保健专业人员开出的,这使其在全球的需求不断升级。
该市场主要由牛皮癣、湿疹、痤疮、酒糟鼻和皮肤癌等皮肤病的日益流行所驱动。此外,老年人口不断增加,更容易受到这类疾病的影响,是另一个主要的增长诱导因素。除此之外,个人正在广泛采用药妆,即具有药物特性的化妆品,以改善皮肤的整体健康和外观。再加上个人对保持健康皮肤的重要性的认识不断提高,对市场增长产生了积极的影响。病人现在更懂得寻求皮肤病的治疗,导致皮肤病药物的整体需求增加。此外,药物输送系统的各种技术进步,如透皮贴剂、纳米技术和微针,正在推动皮肤病药物市场的增长。这些新的给药系统提高了药物的疗效,增强了病人的依从性。此外,消费者可支配收入的增加,非处方药的日益普及,以及对现有治疗方案认识的提高,是创造全球有利市场前景的其他一些因素。
请注意,这只代表部分公司的名单,完整的名单已在报告中提供。
The global dermatological drugs market size reached US$ 21.58 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 39.11 Billion by 2028, exhibiting a growth rate (CAGR) of 10.25% during 2023-2028. The rising prevalence of skin disorders, the increasing demand for cosmeceuticals, and the growing awareness among individuals about skin health represent some of the key factors driving the market.
Dermatological drugs are medications that are used to treat various skin conditions, including acne, psoriasis, eczema, rosacea, skin cancer, fungal infections, and other disorders affecting the skin, hair, and nails. These drugs can be applied topically, orally, or by injection, depending on the type of skin condition being treated. Topical dermatological drugs, including creams, ointments, gels, and sprays, are directly applied to the skin. They are most commonly used to treat localized skin conditions, such as acne or eczema. On the other hand, systemic dermatological drugs are taken orally or by injection and work by targeting the underlying cause of a skin condition. These drugs are often used to treat severe or widespread skin conditions, such as psoriasis. These products have both cosmetic and pharmaceutical properties, and they are designed to improve the overall health and appearance of the skin. Moreover, dermatological drugs are prescribed by dermatologists or other healthcare professionals with expertise in skin health, which is escalating their demand across the globe.
The market is primarily driven by the increasing prevalence of skin disorders such as psoriasis, eczema, acne, rosacea, and skin cancer. In addition, the rising geriatric population that is more susceptible to such ailments represents another major growth-inducing factor. Besides this, individuals are widely adopting cosmeceuticals, which are cosmetic products with pharmaceutical properties to improve the overall health and appearance of the skin. This, coupled with the growing awareness among individuals about the importance of maintaining healthy skin, is positively influencing the market growth. Patients are now more aware of seeking treatment for skin conditions, leading to an increase in the overall demand for dermatological drugs. Moreover, various technological advancements in drug delivery systems, such as transdermal patches, nanotechnology, and microneedles, are driving the growth of the dermatological drugs market. These new drug delivery systems improve the efficacy of drugs and enhance patient compliance. Furthermore, the rising disposable incomes of consumers, the growing popularity of over the counter (OTC) drugs and the increasing awareness regarding the available treatment options are some of the other factors creating a favorable market outlook across the globe.
IMARC Group provides an analysis of the key trends in each segment of the global dermatological drugs market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on dermatological diseases, route of administration, and distribution channel.
Acne
Dermatitis
Psoriasis
Skin Cancer
Others
The report has provided a detailed breakup and analysis of the dermatological drugs market based on the dermatological diseases. This includes acne, dermatitis, psoriasis, skin cancer, and others. According to the report, psoriasis represented the largest segment.
Oral
Parenteral
Topical
A detailed breakup and analysis of the dermatological drugs market based on the route of administration has also been provided in the report. This includes oral, parenteral, and topical. According to the report, parenteral accounted for the largest market share.
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
The report has provided a detailed breakup and analysis of the dermatological drugs market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, and online pharmacies. According to the report, hospital pharmacies represented the largest segment.
North America
United States
Canada
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for dermatological drugs. Some of the factors driving the North America dermatological drugs market included the growing prevalence of skin conditions, the rising awareness regarding appearance, and the escalating demand for cosmeceuticals.
The report has also provided a comprehensive analysis of the competitive landscape in the global dermatological drugs market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include AbbVie Inc., Amgen Inc., Bausch Health Companies Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GSK plc, LEO Pharma A/S (LEO Holding A/S), Novartis AG, Pfizer Inc., Sanofi S.A., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.